Neuroinflammation Research

What "neuroinflammation" means

Neuroinflammation is a research term for immune-type activity in the brain and spinal cord. It is a field and a set of lab and imaging signals, not a diagnosis, a test you can order or a treatment. This page is information only, not medical advice. The labels used below (such as promising but limited, mixed and preclinical (cells/animals only)) are explained in how we label evidence.

The brain has its own support cells, called glial cells. Microglia and astrocytes are glial cells that are also involved in the immune response in the brain. [1] In a healthy brain, microglia engulf and clear waste. [1] For how the nervous and immune systems talk to each other more broadly, see neuroimmune communication.

What the evidence shows, by type

Alzheimer's disease: the best-studied example

A review in a neurology journal describes how misfolded and clumped proteins bind to receptors on microglia and astroglia and trigger an innate immune response, and says the inflammatory mediators released contribute to disease progression and severity. [2] The same review notes that several genes that raise the risk of sporadic Alzheimer's disease code for factors that regulate glial clearance of misfolded proteins and the inflammatory reaction. [2] The National Institute on Aging describes research suggesting that malfunctioning glial cells can release chemicals that cause chronic inflammation and further damage nearby neurons. [1]

Not every microglial response is harmful. A 2023 review reports that single-cell technologies show reactive microglia are highly varied in space and time, and that microglia both clear protein aggregates and, when overloaded, contribute to neuroinflammation and neurodegeneration. [3] That variety is one reason "lower all brain inflammation" is not a sensible goal; see the claim check on reducing all inflammation.

Seeing it: TSPO scans and their limits

Researchers use PET scans that bind a protein called TSPO as a stand-in for neuroinflammation. A critical review says most clinically used TSPO tracers have limitations, including off-target binding and poor binding to a mutated form of TSPO present in up to 30% of the population. [4] A scan signal is a biomarker, not a clinical outcome. See biomarker changes vs meaningful health outcomes.

Testing the idea with drugs

Observational studies pointed one way. A meta-analysis of observational studies found that people who had used non-aspirin NSAIDs (a common class of anti-inflammatory painkillers) had a lower risk of Alzheimer's disease; the combined estimate in prospective studies was 0.74 (95% CI 0.62 to 0.89) for lifetime use. [5] The authors said the timing of use relative to disease still needed exploring. [5]

The randomized trial did not confirm it. The Alzheimer's Disease Anti-inflammatory Prevention Trial enrolled 2,528 adults aged 70 and over with a family history of Alzheimer's disease and compared naproxen, celecoxib and placebo. Neither drug improved cognitive function, and there was weak evidence of a harmful effect for naproxen. [6] A later follow-up found no overall reduction in Alzheimer's risk (hazard ratio for celecoxib versus placebo 1.03, 95% CI 0.72 to 1.50; naproxen 0.92, 95% CI 0.62 to 1.35), after a median of under 1.5 years of treatment. [7] This pair of results shows why observational studies and confounding matter.

Depression is a related, separate question. In a randomized trial of 168 adults with treatment-resistant depression, adding minocycline (a drug the authors describe as inhibiting microglial activation) to usual antidepressants did not beat placebo on the main depression score. [8] A 2026 meta-analysis of 11 trials in people whose blood showed elevated inflammation found small reductions in depressive symptoms (Hedges' g 0.35) but no difference in response or remission rates. [9] These trials measured blood markers and mood, not brain inflammation directly, so they should not be read as proof either way for brain disease.

What this page does not show

• A cell or animal finding about microglia is preclinical (cells/animals only) and is not evidence for a supplement, device or clinic service in people. See cell studies vs animal studies vs human trials.
• Proper evidence not found: we looked for a randomized human trial showing that a "brain inflammation" product bought without a prescription improves a brain disease and did not find one we could read. We did not review individual supplements here.
• Reviews that propose microglia-targeted strategies describe them as "promising" for future therapy, which is a research direction rather than an available treatment. [3]